Molecular Pharmacology (USA), Ltd. (MLPH)

0.0006 0.0000 (0.00%) 收市：09:31AM EDT

Molecular Pharmacology (USA), Ltd.

Drug Discovery Centre
284 Oxford Street Leederville
Perth, WA 6007
Australia
61 8 9443 3011

版塊: Financial Services
行業: Shell Companies
全職員工: 

高階主管

名稱	頭銜	支付	行使價	出生年份
Mr. Jeffrey D. Edwards	CEO, President, CFO & Director	無	無	1951

截止 2013年12月31日為止計算的金額，現金賠償則計算至上一個財政年度末止。薪資是指薪俸、獎金等。已行使價是指財政年度期間已行使的期權價值。貨幣為 USD。

描述

Molecular Pharmacology (USA) Limited, a development stage company, develops and commercializes pain and inflammation management products primarily in Australia and the United States. The company, through its subsidiary, Molecular Pharmacology Pty. Ltd., develops analgesic and anti-inflammatory molecule, known as Tripeptofen for the treatment of common every-day pain. Its products are available in various dosage forms, formulations, line extensions, and package configurations. The company focuses on marketing its products through pharmaceutical distributors, and through collaborative dealings with companies in the United States and Europe. It also has an agreement with Dermatology Development Corporation to develop and market a range of therapeutic, cosmetic, and cosmecutical products based on the ThermaLIFE product range and its active ingredient. The company is based in Perth, Australia. Molecular Pharmacology (USA) Limited is a subsidiary of PharmaNet Group Limited.

公司管治

截至 無 止，Molecular Pharmacology (USA), Ltd. 的 ISS 管治質素評分為 無。 Pillar 分數正在審核中：無；董事會：無；股東權利：無；現金賠償：無。

企業管治評分的資料提供： Institutional Shareholder Services (ISS). 評分將以 1 至 10 分顯示 (與指數或地區相關)。1 分表示較低的管治風險，而 10 分表示較高的管治風險。